NCT07906145
A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Safety and Tolerability of QLS2416 Injection
Timeframe: Up to 24 weeks
Secondary (6)
Pharmacokinetic Profile of QLS2416
Anti-Drug Antibody
SLE Responder Index (SRI) and Other SLE Disease Activity Measures
RA Disease Activity Measures
pSS Disease Activity Measures
Show 1 moreShow less
SSc Disease Activity Measures
Arms and interventions
QLS2416Experimental
Dose Escalation Part: Participants with active SLE, RA, or pSS will receive single ascending subcutaneous doses of QLS2416 injection across 7 dose levels (0.025 mg to 6.0 mg). Dose Expansion Part: Participants with active SLE or SSc will receive multiple dosing of QLS2416 injection at 3 dose levels within the 4-week treatment period.
Drugs: QLS2416 Injection